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Population Pharmacokinetics and Pharmacodynamics of ExtendedInfusion Piperacillin and Tazobactam in Critically Ill Children
Kristen Nichols,a,b Eun Kyoung Chung,c* Chad A. Knoderer,a Lauren E. Buenger,b Daniel P. Healy,d Jennifer Dees,d
Ashley S. Crumby,b,c* Michael B. Kaysc
Butler University College of Pharmacy and Health Sciences, Indianapolis, Indiana, USAa; Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USAb;
Purdue University College of Pharmacy, West Lafayette and Indianapolis, Indiana, USAc; James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio,
USAd

iperacillin-tazobactam (TZP) is a broad-spectrum ␤-lactam–
␤-lactamase inhibitor antibiotic that is commonly used in
children with suspected or documented infection. For penicillin
antibiotics like piperacillin, microbiological and clinical outcomes
are associated with the cumulative percentage of the dosing interval that the drug concentration exceeds the MIC for the organism(s) under steady-state pharmacokinetic conditions (TMIC);
optimal activity is seen when the TMIC is ⱖ50% (1, 2). Prolongation of the infusion time is one strategy that has been utilized to
increase the TMIC and optimize the pharmacodynamics of TZP,
particularly for isolates with elevated MICs (1). Administration of
TZP every 8 h with an infusion time of 4 h has been well described
in adult patients (3–12). It has been demonstrated that 3.375 g
given every 8 h and infused over 4 h achieves pharmacodynamic
targets as effectively as 3.375 g given every 6 h, while it utilizes less
total drug per day, resulting in a cost reduction (9, 10). Additionally, data support the improvement of clinical outcomes with extended-infusion dosing regimens compared to those achieved
with traditional dosing regimens (4, 5).
Extended-infusion TZP dosing (with a piperacillin component
of 100 mg/kg of body weight given every 8 h and infused over 4 h)
was demonstrated to be feasible in over 90% of children, but currently available pediatric data on the pharmacodynamics of extended-infusion TZP are limited to those from Monte Carlo simulations incorporating pharmacokinetic data derived from the
single or first dose of TZP infused over 0.5 h (13–16). Children
exhibit pharmacokinetic changes throughout development, and
the pharmacokinetics of drugs in children show significant differences from those in adults. Dose extrapolation from adults to
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children has been shown to be associated with adverse outcomes
(17–19). While pharmacodynamic principles for many drugs can
change significantly from childhood to adulthood, antibiotics are
unique in that the target exposures for efficacy are based on the
interaction between the antibiotic and the infecting organism.
Pharmacodynamic predictors of efficacy (e.g., TMIC) for antibiotics do not change from the adult to the child. While evaluations of
TZP pharmacokinetics in children are available, there are currently no published pharmacokinetic and pharmacodynamic data
from children receiving extended-infusion TZP to guide optimal
dosing on the basis of attainment of the target TMIC (14, 15, 20–
28). In addition, data regarding the population pharmacokinetics
of tazobactam in children are limited (27, 28).
The objective of this study was to determine the steady-state
population pharmacokinetics of piperacillin and tazobactam
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The study objective was to evaluate the population pharmacokinetics and pharmacodynamics of extended-infusion piperacillintazobactam in children hospitalized in an intensive care unit. Seventy-two serum samples were collected at steady state from 12
patients who received piperacillin-tazobactam at 100/12.5 mg/kg of body weight every 8 h infused over 4 h. Population pharmacokinetic analyses were performed using NONMEM, and Monte Carlo simulations were performed to estimate the piperacillin
pharmacokinetic profiles for dosing regimens of 80 to 100 mg/kg of the piperacillin component given every 6 to 8 h and infused
over 0.5, 3, or 4 h. The probability of target attainment (PTA) for a cumulative percentage of the dosing interval that the drug
concentration exceeds the MIC under steady-state pharmacokinetic conditions (TMIC) of >50% was calculated at MICs ranging
from 0.25 to 64 mg/liter. The mean ⴞ standard deviation (SD) age, weight, and estimated glomerular filtration rate were 5 ⴞ 3
years, 17 ⴞ 6.2 kg, and 118 ⴞ 41 ml/min/1.73 m2, respectively. A one-compartment model with zero-order input and first-order
elimination best fit the pharmacokinetic data for both drugs. Weight was significantly associated with piperacillin clearance, and
weight and sex were significantly associated with tazobactam clearance. Pharmacokinetic parameters (mean ⴞ SD) for piperacillin and tazobactam were as follows: clearance, 0.22 ⴞ 0.07 and 0.19 ⴞ 0.07 liter/h/kg, respectively; volume of distribution, 0.43 ⴞ
0.16 and 0.37 ⴞ 0.14 liter/kg, respectively. All extended-infusion regimens achieved PTAs of >90% at MICs of <16 mg/liter.
Only the 3-h infusion regimens given every 6 h achieved PTAs of >90% at an MIC of 32 mg/liter. For susceptible bacterial pathogens, piperacillin-tazobactam doses of >80/10 mg/kg given every 8 h and infused over 4 h achieve adequate pharmacodynamic
exposures in critically ill children.

Extended-Infusion Piperacillin-Tazobactam in Children

when administered by extended infusion in children hospitalized
in a pediatric intensive care unit (ICU). Additionally, we evaluated
the pharmacodynamics of TZP using various dosing regimens and
infusion times over a range of MICs to determine the optimal
dosing regimens in this patient population.
MATERIALS AND METHODS
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Patient population. Patients 9 months to 11 years of age who were admitted to a pediatric intensive care unit were eligible for the study if they were
already receiving extended-infusion TZP as part of routine care for a
suspected or proven bacterial infection. Patients had to have received at
least one prior dose to qualify for the study, and adequate vascular access
was required to obtain serum samples without additional venipuncture.
Patients with an estimated glomerular filtration rate (eGFR) of ⬍60 ml/
min/1.73 m2, as determined by the modified Schwartz equation (29), were
excluded, as were patients receiving any form of dialysis or renal replacement therapy. The study was approved by the Institutional Review Board
at Indiana University, and written informed consent was obtained from
the parent or legal guardian of each child prior to sample collection. Written informed assent was obtained from children who were awake, cognitively appropriate, and capable of understanding the assent process.
Study design and blood sampling. Dosing regimens were prescribed
by the treating physician as part of routine care. TZP was dosed at 100
mg/kg of the piperacillin component (112.5 mg/kg of total TZP) every 8 h
infused over 4 h up to a usual adult dose of 3,000 mg of the piperacillin
component and 375 mg of the tazobactam component per dose, according to a dosing protocol approved by the Pharmacy and Therapeutics
Committee at the institution. TZP was provided in a labeled syringe by the
hospital pharmacy for each patient from a stock dilution of 112.5 mg of
TZP per ml. Blood samples were collected at steady state from an alreadypresent indwelling intravenous or intra-arterial catheter which was not
utilized for TZP administration. Samples were obtained from each patient
immediately prior to the study dose and at 2, 4 (end of infusion), 5, 6, and
8 h after the start of the infusion of the study dose. At each time point, 0.5
ml/kg (maximum, 5 ml) of whole blood was collected in non-anticoagulant-containing (red-top) tubes. After the blood was allowed to coagulate,
samples were centrifuged, and serum samples were stored frozen at ⫺70°C.
Serum samples were shipped on dry ice by overnight carrier to the University
of Cincinnati Academic Health Center (Cincinnati, OH) for determination of
piperacillin and tazobactam concentrations.
Piperacillin and tazobactam assay. Piperacillin and tazobactam concentrations were measured using a validated high-performance liquid
chromatography (HPLC) assay, as described previously (12, 30). The
standard curve for piperacillin was linear over the concentration range of
2 to 400 mg/liter (r ⱖ0.993). The within-day (n ⫽ 6) and between-day
(n ⫽ 8) coefficients of variation for control specimens spiked with piperacillin were less than 8%. The standard curve for tazobactam was linear
over the concentration range of 2 to 100 mg/liter (r ⱖ 0.991). The withinday and between-day coefficients of variation for control specimens
spiked with tazobactam ranged from 3.9% to 10.8% over the concentration range tested. The limit of quantification for both drugs was considered to be the lowest standard concentration.
Population pharmacokinetic modeling. Serum concentration-time
data for piperacillin and tazobactam from all individual patients were
analyzed simultaneously by a population compartmental pharmacokinetic modeling approach using NONMEM (version VII; Globomax LLC,
Ellicott City, MD, USA), as previously described (11). Pharmacokinetic
models were built separately for piperacillin and tazobactam. For both
drugs, the first-order conditional estimation method with interaction was
used. On the basis of previous publications describing piperacillin pharmacokinetics in children, one- and two-compartment models with zeroorder input and first-order (i.e., linear) elimination were evaluated as
potential structural pharmacokinetic models for both piperacillin and
tazobactam. The interindividual variability () of the population
pharmacokinetic parameters was assumed to follow a log-normal dis-

tribution with a mean of zero and a variance of 2 (31). Possible
correlations among the interindividual variabilities for pharmacokinetic parameters in the model were examined using the OMEGA
BLOCK functionality in NONMEM.
For residual errors (ε) unexplained by the model, additive (εadd), proportional (εprop), and combinational models were evaluated, and residual
error was assumed to be normally distributed with a mean of zero and a
variance of 2 (31). The best structural pharmacokinetic models with
stochastic error terms for piperacillin and tazobactam were selected on the
basis of the visual inspection of observed concentration-time plots, goodness-of-fit plots, individual plots of observed and individual predicted
concentration-time profiles, relative standard errors, the change in the
minimum objective function value (OFV), and the Akaike information
criterion (32). Standard errors were deemed acceptable if they were ⬍50%
for fixed effects and ⬍75% for random effects.
The final pharmacokinetic model was built by evaluating the effects of
covariates on the pharmacokinetic parameters of piperacillin and tazobactam using stepwise forward inclusion (decrease in the OFV by ⬎3.84;
P ⬍ 0.05; 2 distribution; 1 degree of freedom [df]) followed by the backward elimination process (increase in the OFV by ⬎5.024; P ⬍ 0.025; 2
distribution; 1 df) as previously described, with modified covariates (27).
The covariates tested included age (in years); sex; height (in centimeters);
body size descriptors, including body weight (WT; in kilograms) and
body mass index (BMI), calculated as WT (in kilograms) divided by
height (in meters) squared; and eGFR, as calculated by the modified
Schwartz equation (29). Continuous covariates (e.g., age; height; body
size descriptor, including WT and BMI; and eGFR) were centered at their
median values. The full model was constructed when all significant covariates were added to the model in the stepwise forward inclusion process.
Throughout the covariate model-building process, in addition to the
model OFV, shrinkage and standard errors were used to evaluate the
interindividual variability term of the PK parameters. Acceptable standard error criteria for random and fixed effects were previously described.
Covariate models with shrinkage values of ⬍30% were considered appropriate. The physiologic plausibility of the relationship between each covariate and pharmacokinetic parameter in the model was evaluated as well.
The final model was evaluated by the use of goodness-of-fit plots and
individual plots of the observed and individual predicted concentrationtime profiles. The predictive accuracy of the final pharmacokinetic model
was examined by visual predictive checks (VPCs) (33). Visual predictive
checks were performed by simulating the serum concentration-time profiles for piperacillin and tazobactam using NONMEM (version VII;
Globomax LLC, Ellicott City, MD, USA). One thousand simulations were
conducted to create serum concentration-time profiles of piperacillin and
tazobactam for 12,000 virtual patients, using the data for all of the study
patients included in this study to build the population pharmacokinetic
model (n ⫽ 12). Curves for the 5th, 50th, and 95th percentiles of simulated drug concentrations were graphed with the observed concentrations. Descriptive statistics were used to summarize patient demographics
and pharmacokinetic parameters.
Monte Carlo simulations. Pharmacodynamic exposures were modeled for the following TZP dosing regimens: 80/10 mg/kg every 8 h, 80/10
mg/kg every 6 h, 100/12.5 mg/kg every 8 h, and 100/12.5 mg/kg every 6 h.
Each dosing regimen was simulated as a 0.5-h infusion, a 3-h infusion
for regimens of administration every 6 h, and a 4-h infusion for regimens of administration every 8 h. Monte Carlo simulations for
piperacillin were performed on the basis of our study patient characteristics using NONMEM to create steady-state serum piperacillin concentration-time curves for 5,040 virtual patients using the final population pharmacokinetic model per dosing regimen. All serum
concentration-time curves were simulated in 0.1-h intervals, and the
unbound serum concentrations were calculated as the simulated serum drug concentrations multiplied by the unbound fraction, which
was assumed to be 0.7 for piperacillin (34). On the basis of the simulated unbound serum concentration-time profiles, the probability of
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Sex

20

9.6

30.1

9.5
10
14.5
16.8
23

11.9
19.7

18.8

20

Wt (kg)

2,081.25

1,078

3,375

1,070
1,125
1,630
1,860
2,600

1,465
2,200

2,100

2,250

TZP dosea (mg)

122

129

90

86
102
98
189
105

93
107

98

106

eGFRb

Cornelia de Lange
syndrome, epilepsy

Previously healthy, HHV
encephalitis

CCHD
Laryngomalacia
Epilepsy, microcephaly
CCHD, CLD
Heart transplant, B cell
lymphoma
Optic glioma

Previously healthy, ARDS
s/p MVA with TBI

CCHD, tracheostomy

CP, small bowel resection
s/p volvulus

Underlying disease
process(es)
Infectious indication

Pneumonia

Neutropenic fever,
typhlitis
VAP

Suspected sepsis
Pneumonia
Pneumonia
Open sternum
Pneumonia

Pneumonia
Pneumonia

VAP

Sepsis due to CLABSI

Empirical

Directed

Empirical

Empirical
Empirical
Empirical
Empirical
Empirical

Empirical
Empirical

Directed

Directed

Type of therapy

Site, isolated organism(s)

Fluid from mini-BAL, Enterobacter
cloacae
Fluid from mini-BAL, Haemophilus
influenzae
Fluid from mini-BAL, S. aureus
(MRSA)

Blood, Bacteroides ovatus

Blood, Klebsiella pneumoniae
Blood, CoNS
Blood, Enterococcus faecalis
Fluid from mini-BAL, P. aeruginosa
Fluid from mini-BAL, Serratia
marcescens
None
Fluid from mini-BAL,
Staphylococcus aureus (MSSA)
None
Adenovirus
Influenza A virus
None
None

Blood, Candida parapsilosis

NR

␤-Lactamase negative

NR (P ⱕ 4)

NR

NR

8
NR
NR
1
NR

TZP MIC (mg/liter)

b

All doses were administered every 8 h.
eGFR values are reported in ml/min/1.73 m2 and were rounded to the nearest whole number.
c
Abbreviations: ARDS, acute respiratory distress syndrome; BAL, bronchoalveolar lavage; CCHD, complex congenital heart disease; CLABSI, central line-associated bloodstream infection; CLD, chronic liver disease; CoNS, coagulasenegative Staphylococcus; CP, cerebral palsy; eGFR, estimated glomerular filtration rate (determined bedside by the modified Schwartz equation [29]); F, female; HHV, human herpesvirus; M, male; MRSA, methicillin-resistant
Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; MVA, motor vehicle accident; NR, not reported; P, piperacillin; s/p, status post; TBI, traumatic brain injury; VAP, ventilator-associated pneumonia.
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TABLE 1 Individual baseline characteristics of study patientsc

Nichols et al.

Extended-Infusion Piperacillin-Tazobactam in Children

TABLE 2 Final population pharmacokinetic model parameters of piperacillin and tazobactama
Final piperacillin model

Final tazobactam model

Estimate (% SE)

% shrinkage

Estimate (% SE)

% shrinkage

1 (liters/h)
2 (liters)
3
4 (liters/h)

3.51 (6.5)
6.58 (10.6)
0.0814 (45.1)
NA

NA
NA
NA
NA

3.43 (5.9)
5.54 (8.9)
⫺0.285 (20.9)
0.0676 (38.6)

NA
NA
NA
NA

Interindividual variability ()
CL
V

17.3% (59.0)
25.2% (59.1)

10.3%
18.0%

13.1% (52.1)
NA

11.2%
NA

Residual error ()
proportional
additive

25.3% (28.7)
NA

10.3%
NA

27.2% (35.2)
0.76 mg/liter (47.8)

5.8%
5.8%

The final piperacillin model was TVCL ⫽ 1 ⫹ [3 · (WT ⫺ 18)] and TVV ⫽ 2. The final tazobactam model was TVCL ⫽ [1 · (1 ⫹ 3 · sex)] ⫹ [4 · (WT ⫺ 18)] and TVV ⫽ 2,
where sex is coded 1 if female and 0 otherwise, TVCL is the typical population value of clearance (in liters per hour), WT is body weight (in kilograms), and TVV is the typical
population value of the volume of distribution (in liters). NA, not applicable.
a

target attainment (PTA) for piperacillin was calculated for each dosing
regimen using the pharmacodynamic targets of TMICs of ⱖ50% and
100% at specific MICs ranging from 0.25 to 64 mg/liter (15, 35).

RESULTS

Patients. Twelve patients who were receiving care in the pediatric
intensive care unit at our institution participated in the study.
Table 1 shows select demographics, TZP doses, infectious indications, and any organisms isolated for each patient. The median
age, height, weight, and eGFR were 5 years (interquartile range
[IQR], 1.75, 6.5 years), 103 cm (IQR, 81.75, 109.25 cm), 17.8 kg
(IQR, 11.4, 20 kg), and 103 ml/min/1.73 m2 (IQR, 96, 111 ml/min/
1.73 m2), respectively. The patients received a mean ⫾ standard
deviation (SD) TZP dose of 112.4 mg/kg ⫾ 4.1 mg/kg and 1,903
mg ⫾ 686 mg. Patients had received a median of 5 doses (range, 2
to 11 doses) before the study dose. TZP appeared to be well tolerated during the study.
Population pharmacokinetic analysis. Seventy-two piperacillin and tazobactam concentrations (6 samples from each of 12
patients) were included. The observed serum concentration-time
profiles of piperacillin and tazobactam were best described by a
one-compartment model with zero-order input and first-order
(linear) elimination. The model-derived pharmacokinetic parameters for piperacillin and tazobactam were clearance (CL) and volume of distribution (V). For piperacillin, interindividual variability was estimated for both CL and V. The model did not support
the correlation between CL and V (change in OFV [⌬OFV] ⫽
⫺0.783, correlation coefficient between CL and V [CL-V] ⫽
38.8%). Residual error was best modeled by the proportional
form. For tazobactam, interindividual variability was estimated
only for CL. Addition of the interindividual variability term on V
did not significantly decrease the model OFV (⌬OFV ⫽ ⫺1.601).
Also, the standard error and the shrinkage value associated with
the interindividual variability term on V were large (⬎100% and
⬎30%, respectively) (36, 37). Therefore, the interindividual variability term on V was not estimated. Residual error was best modeled by the combinational form.
Covariates that significantly decreased the model OFV and interindividual variability in the stepwise forward process were WT
added to piperacillin CL (⌬OFV ⫽ ⫺4.517) and sex (where 1 was
used for female and 0 was used for male), followed by WT added to

January 2016 Volume 60 Number 1

tazobactam CL (⌬OFV ⫽ ⫺4.402 for sex; ⌬OFV ⫽ ⫺7.528 for
WT). None of these covariates were removed from the models in
the backward elimination step. Therefore, the final model for piperacillin (OFV ⫽ 448.641) was CL (in liters per hour) ⫽ 3.51 ⫹
[0.0814 · (WT ⫺ 18)], and V was equal to 6.58 liters. The final
model for tazobactam (OFV ⫽ 195.425) was CL (in liters per
hour) ⫽ {3.43 · [1 ⫺ (0.285 · sex)]} ⫹ [0.0676 · (WT ⫺ 18)], and
V was equal to 5.54 liters.
Table 2 summarizes the model-estimated population pharmacokinetic parameters and their associated interindividual variability for piperacillin and tazobactam. Figures 1 and 2 show basic
goodness-of-fit plots for the final population pharmacokinetic
models for piperacillin and tazobactam, respectively. For piperacillin, the final model appeared to slightly underpredict the observed concentrations at high observed concentrations (⬎130 mg/
liter). For tazobactam, few data points were notably deviated from
the line of identity near the observed tazobactam concentrations
of 5, 10, and 20 mg/liter. Overall, the goodness-of-fit plots demonstrated no apparent systematic bias for the final pharmacokinetic models for both piperacillin and tazobactam. Visual predictive checks with the 90% prediction intervals using the final
population pharmacokinetic model graphed with the observed
drug concentrations are shown in Fig. 3a and b for piperacillin and
tazobactam, respectively. On the basis of the VPC plots (Fig. 3a
and b), the final models adequately predicted the observed drug
concentrations, with most of the observed data being within the
90% prediction interval. Table 3 summarizes the values for the
piperacillin and tazobactam pharmacokinetic parameters estimated by the final models.
Monte Carlo simulation. Figure 4 shows the PTA for piperacillin at the pharmacodynamic targets of TMICs of ⱖ50% and
ⱖ100% for the TZP dosing regimens evaluated. At the pharmacodynamic target of a TMIC of ⱖ50% (Fig. 4a), all simulated dosing regimens achieved a PTA of ⬎90% at MICs of ⱕ8 mg/liter.
Only 0.5-h infusion regimens of 80 mg/kg and 100 mg/kg every 8
h did not achieve a PTA of ⬎90% at an MIC of 16 mg/liter. At an
MIC of 32 mg/liter, 80 to 100 mg/kg given every 6 h and infused
over 3 h achieved a PTA of ⬎90%.
At the pharmacodynamic target of a TMIC of 100% (Fig. 4b),
none of the regimens achieved a PTA of ⬎90% at an MIC of ⱖ16
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mg/liter, and only 100 mg/kg given every 6 h and infused over 3 h
achieved a PTA of ⬎90% at an MIC of 8 mg/liter.
DISCUSSION

To our knowledge, this is the first study to evaluate the pharmacokinetics and pharmacodynamics of extended-infusion TZP in
children hospitalized in an intensive care unit. The population
pharmacokinetic model that best described the observed serum
concentration-time data for piperacillin and tazobactam was a
one-compartment model with first-order (linear) elimination.
The same population pharmacokinetic model was recently described for adults receiving TZP by extended infusion (11), and a
one-compartment model has best described extended-infusion
pharmacokinetic data for ␤-lactams in adults (10, 12, 38, 39).
Previous studies have utilized one- and two-compartment models
to describe piperacillin and/or tazobactam serum concentrationtime data in pediatric patients receiving TZP by the traditional
0.5-h infusion (14, 15, 24, 27, 28, 40). However, the rate constants
for the transfer of piperacillin between the central and peripheral
compartments are rapid in young children and distribution may
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be complete (or nearly complete) by the end of the 4-h infusion,
which results in a better fit with a one-compartment model (14).
Piperacillin CL was significantly associated with weight, and tazobactam CL was significantly associated with weight and sex (Table
2). Female patients exhibited significantly slower tazobactam CL
than male patients, a finding that has not been previously reported. The glomerular filtration rate (GFR), estimated using the
modified Schwartz equation (29), was not associated with piperacillin or tazobactam CL, similar to the findings of previous studies
(14, 15). Potential explanations for this finding include the relatively small sample size (n ⫽ 12), the exclusion of patients with an
eGFR of ⬍60 ml/min/1.73 m2, or an inaccurate estimate of the
patient’s actual GFR.
Due to the extended infusion time, maximum serum concentrations (Cmaxs) for piperacillin and tazobactam were substantially lower in the present study than in previous studies where
comparable doses were infused over 0.5 h (20, 22). The lower Cmax
is not likely to adversely impact clinical outcomes in children,
since ␤-lactams exhibit time-dependent bactericidal activity and
TMIC predicts outcome. It is currently unknown whether a lower

Antimicrobial Agents and Chemotherapy
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FIG 1 Goodness-of-fit plot of the final piperacillin pharmacokinetic model.

Extended-Infusion Piperacillin-Tazobactam in Children

Cmax might result in fewer adverse events. On the other hand, the
minimum serum concentrations (Cmins) at 8 h in the present
study were similar to the concentrations at 4 h in the previous
study (20). In the present study, piperacillin CL was slower and V
was larger than those in the study by Reed and colleagues (20).
They enrolled pediatric patients with suspected or proven bacterial infections outside the central nervous system, but they did not
report the actual infection-related diagnoses for the patients. Differences in CL and V may be due to physiologic changes related to
the infection, some degree of undetected renal dysfunction, or
severity of illness, since all of our patients were hospitalized in an
intensive care unit. Differences may also be related to the small
sample size and age groupings selected for this study. Piperacillin
CL was faster and V was larger in a study by Cies and colleagues,
but differences in pharmacokinetic parameters between these
studies may be due to the physiologic changes associated with
sepsis and burn injury (14). Eleven of their 13 patients were diagnosed with sepsis, and 3 patients were admitted with burn injury.
As patients in the ICU may be infected with less susceptible
bacteria and because the margin for error may be low, more ag-

January 2016 Volume 60 Number 1

gressive dosing for empirical therapy may be warranted to provide
adequate pharmacodynamic exposures before susceptibility data
are known. In an evaluation of 30-day mortality in children who
received TZP for the treatment of Pseudomonas aeruginosa bacteremia, 72% of isolates had TZP MICs of ⱕ16 mg/liter and 28%
had MICs of 32 or 64 mg/liter (41). Mortality was significantly
higher in children infected with the less susceptible strains (41). At
an MIC of 32 mg/liter, only 3-h infusions of 80 to 100 mg/kg every
6 h in our study achieved a PTA of ⬎90%, while none of the
regimens achieved optimal exposures at an MIC of 64 mg/liter.
Depending on the MIC distribution at an individual institution,
less aggressive empirical dosing regimens may be possible if isolates with elevated MICs are infrequent. It may be appropriate to
utilize standard FDA-approved dosing regimens or decrease the
empirical extended-infusion dose after the MIC of the infecting
pathogen is known, depending on the site and severity of the infection. Our data suggest equivalent exposures between traditional and extended-infusion regimens for pathogens with MICs
of ⱕ8 mg/liter. Extended-infusion regimens, including the 80mg/kg regimen given every 8 h, demonstrated an acceptable PTA
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FIG 2 Goodness-of-fit plot of the final tazobactam pharmacokinetic model.
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(TMIC ⬎ 50%) against isolates with slightly elevated MICs of 16
mg/liter. However, this potential for dose deescalation should be
weighed against the pharmacokinetic variability between patients
and the potential labor associated with alteration of the doses.
In addition to improved clinical outcomes, evaluations of extended-infusion TZP in adults have demonstrated a financial benefit. Extended infusions allow administration of the same dose
every 8 h instead of every 6 h, thus eliminating the nursing, pharmacy, and medication costs of 1 dose of TZP per patient on every
day of therapy. Our patients received 4-h infusions of 100/12.5
mg/kg every 8 h during this study, which is the current dosing
protocol at the Riley Hospital for Children. For stable patients
who demonstrate infection with a pathogen with an MIC of ⱕ16
mg/liter, employing a dose of 80/10 mg/kg given every 8 h and
infused over 4 h would potentially result in a cost benefit by decreasing the medication cost via lowering of the total daily dose.
For similar dosing regimens, the present study tended to predict PTAs higher than those predicted by previous studies (13, 14).
These differences in PTAs are likely explained by the differences in
pharmacokinetic parameters described previously. Courter and
colleagues (13) performed Monte Carlo simulations incorporating the pharmacokinetic data reported by Reed and colleagues
(20). Their simulations predicted lower PTAs across a range of
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FIG 3 Visual predictive checks for piperacillin (a) and tazobactam (b) at
100/12.5 mg/kg every 8 h infused over 4 h.
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TABLE 3 Piperacillin and tazobactam pharmacokinetic parameters estimated by the final population pharmacokinetic modelc

Tazobactam concentration (mg/L)

25

V (liter/kg)

30

January 2016 Volume 60 Number 1

Downloaded from http://aac.asm.org/ on December 31, 2015 by guest

0

At the actual studied doses given to the patients in the study.
Fixed. No interindividual variability was estimated.
c
Data represent the mean ⫾ SD (range) for 12 patients for each drug. Abbreviations: Cmax, maximum observed serum concentration; Cmin, minimum observed serum concentration; CL, clearance; V, volume of distribution; k,
elimination rate constant; t1/2, terminal elimination half-life; AUC0 –, area under the serum concentration-time curve for one dosing interval (i.e., 8 h in this study) at steady state.
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FIG 4 PTA for piperacillin at a TMIC of ⱖ50% (a) and a TMIC of 100% (b) for
4 intermittent-infusion and 4 prolonged-infusion regimens of piperacillintazobactam at specific MICs in critically ill children. The dashed, horizontal
line represents a PTA of 90%. TMIC, the cumulative percentage of the dosing
interval that the drug concentration exceeds the MIC for the organism(s)
under steady-state pharmacokinetic conditions; q8h, every 8 h; q6h, every 6 h.

doses, most notably, a lack of optimal exposures with 0.5-h infusion regimens (13). Similarly, Cies and colleagues found PTAs for
the lowest 0.5-h infusion dose in critically ill children that were
slightly lower than those that we found in our study (14). A 4-h
infusion of 100 mg/kg every 8 h was not simulated in their study,
but it is likely that it would have achieved optimal pharmacodynamics at 16 mg/liter, similar to our findings (14). Cies and colleagues reported PTAs similar to those found in our study for
various regimens in patients with febrile neutropenia (15). The
values of the pharmacokinetic parameters were similar between
the 2 studies, a finding which likely explains the comparable PTAs.
When this information is applied to clinical practice, it is important to note that only serum concentrations were measured in
these studies, and the pharmacokinetics of TZP in tissues and at
the site of the infection are unknown. While this information may
be used to predict doses that achieve PTAs of ⱖ90% for bloodstream infections, it is possible that target attainment is underpredicted for urinary tract infections and overpredicted for more
deep-seated infections. Optimal dosing for pneumonia, abscesses,
and intra-abdominal infections may be higher than that for isolated bloodstream infections caused by organisms with the same
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MIC. Additionally, though our pharmacokinetic data should not
be extrapolated to nonrepresentative populations, certain infections or patient populations may require a TMIC of ⬎50% for
optimal bactericidal activity (15). As a result, it may be prudent to
target a higher TMIC, strengthening the argument for empirical or
directed 4-h infusion regimens in certain patient populations even
when traditionally infused doses are likely to achieve a target of a
TMIC of 50%.
Dosing simulations were performed on the basis of the pharmacokinetics and the target pharmacodynamic parameter for
the piperacillin component only, but tazobactam pharmacokinetics and pharmacodynamics should not be ignored. Adequate
amounts of the ␤-lactamase inhibitor are required to preserve the
activity of the ␤-lactam agent against organisms producing inhibitor-susceptible ␤-lactamases (42–44). The optimal pharmacodynamic target for tazobactam against multiple ␤-lactamases has not
been well characterized, especially in pediatric patients, so the dosing recommendations in our study are based on the findings for
the piperacillin component only. Additional studies are needed to
determine the target tazobactam pharmacodynamic parameter
for maximum inhibition for multiple common ␤-lactamases.
There are some limitations that should be considered when
evaluating the results of this study. The number of patients evaluated is relatively small (n ⫽ 12), and six samples were collected
from each patient. Seventy-two samples may not be sufficient to
provide robust estimates of pharmacokinetic parameters in a population of pediatric patients hospitalized in an ICU. However,
previous studies incorporated only 31 and 48 piperacillin concentrations into development of the population pharmacokinetic
models (14, 15). Therefore, the number of piperacillin and tazobactam concentrations was greater in this study. The presence of
concomitant medications such as vasopressors, which could impact the disposition of TZP, was not evaluated. The study results
may not be applicable to younger infants or older children, since
the children completing this study were 1 to 9 years of age. Underlying conditions were limited in our population and may not adequately predict the range of possible piperacillin exposures for
patients with other underlying conditions. Monte Carlo simulations for the 0.5-h and extended-infusion dosing regimens were
performed using the piperacillin pharmacokinetic parameters estimated using a one-compartment model. Piperacillin exhibits bior triexponential pharmacokinetics when infused over 0.5 h or
less. The use of a one-compartment model to simulate dosing
regimens infused over 0.5 h may not accurately estimate the serum
concentration-time profiles for piperacillin, which may affect the
PTA data. Therefore, clinicians should exercise caution when interpreting the PTA data for 0.5-h infusion regimens.
In conclusion, the pharmacokinetics of piperacillin and tazobactam administered as an extended infusion to children in an
ICU differed slightly from those in previous studies infusing TZP
over 0.5 h. These differences may be due to the patient population
studied and their underlying conditions. For bacterial pathogens
with MICs of ⱕ8 mg/liter, extended-infusion dosing regimens do
not substantially improve PTA, and standard dosing regimens are
likely sufficient. However, 100/12.5 mg/kg of TZP administered as
an extended infusion every 6 to 8 h may be considered for empirical or directed therapy in critically ill pediatric patients with infections caused by less susceptible pathogens or if the desirable
TMIC is greater than 50%. The optimal empirical regimens will be
impacted by the typical pathogens and MIC distributions encoun-
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tered at a given institution. Prospective studies comparing outcomes in children receiving traditional and extended-infusion
dosing regimens are needed.
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